{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Viridian Therapeutics, Inc. "},"Symbol":{"label":"Symbol","value":"VRDN"},"Address":{"label":"Address","value":"221 CRESCENT STREET,SUITE 401, WALTHAM, Massachusetts, 02453, United States"},"Phone":{"label":"Phone","value":"+1 617 272-4600"},"Industry":{"label":"Industry","value":"Medical Specialities"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease."},"CompanyUrl":{"label":"Company Url","value":"https://www.viridiantherapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Angela Liu Sheen","title":"Vice President-Research & Development Operations"},{"name":"Stephen Frank Mahoney","title":"President, Chief Executive Officer & Director"},{"name":"Thomas A. Ciulla","title":"Chief Medical Officer"},{"name":"Thomas W. Beetham","title":"Chief Operating Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}